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Abstract: Lithistid sponges are known to produce a diverse array of compounds ranging 
from polyketides, cyclic and linear peptides, alkaloids, pigments, lipids, and sterols.   
A majority of these structurally complex compounds have very potent and interesting 
biological activities. It has been a decade since a thorough review has been published that 
summarizes the literature on the natural products reported from this amazing sponge order. 
This review provides an update on the current taxonomic classification of the Lithistida, 
describes structures and biological activities of 131 new natural products, and discusses 
highlights from the total syntheses of 16 compounds from marine sponges of the Order 
Lithistida providing a compilation of the literature since the last review published in 2002.  
Keywords: Lithistida; lithistid; Theonella; desmas; natural product 
 
1. Introduction  
The Order Lithistida is a polyphyletic assemblage of sponges grouped together based on interlocking 
siliceous spicules called desmas that make up their skeleton [1,2]. The degree to which the desmas 
interlock result in lithistid sponges having a firm or rock-hard consistency [1,2]. Many lithistid 
families and genera have skeletal characteristics that suggest a closer phylogenetic relationship with 
other sponge taxa. For example, the family Corallistidae is also characterized by the presence of 
microscleres (amphiasters) that are similar to those found in the Order Astrophorida, Family 
Pachastrellidae. For many lithistid families and genera, however, skeletal similarities are not as 
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obvious, and until other characters (e.g., molecular data) can be evaluated and analyzed, these   
desma-bearing sponges will continue to be grouped in the Order Lithistida. A summary of the current 
taxonomic classification is shown in Figure 1. 
Figure 1. Current classification of lithistid sponges [3].  
 
Lithistid sponges occur world-wide in both shallow and deep water environments [4]. They are 
known to produce over 300 different interesting and diverse compounds comprising of polyketides, 
cyclic and linear peptides, alkaloids, pigments, lipids, and sterols [1,5,6]. Some of their compound 
diversity has been attributed to the symbiotic microorganisms that reside within the sponge [1,7–9]. 
There have been a few excellent reviews published previously which have highlighted the compounds 
isolated from lithistid sponges through the year 2000 [1,5,6,10]. A recent review was published that 
highlighted a subset of bioactive lithistid compounds along with their mechanisms of action [10]. Since 
the last full review published in 2002, 131 compounds have been reported and substantial success has 
been achieved in the synthesis of compounds reported from the Lithistida. This review provides an 
update on the isolation of compounds reported from marine sponges of the Order Lithistida and 
highlights some of the total synthetic efforts reported since the last review published in 2002 [5]. 
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2. Cyclic Peptides  
The literature has been dominated by isolations of cyclic peptides from different species within the 
genus Theonella [11]. Since 2000, 51 new cyclic peptides have been reported from five different 
genera of lithistid sponges [11].  
Theopapuamide A (1) is a cytotoxic undecapeptide isolated from Theonella swinhoei collected off 
Milne Bay, Papua New Guinea (Figure 2) [12]. It is the first natural peptide containing   
β-methoxyasparagine and 4-amino-5-methyl-2,3,5-trihydroxyhexanoic acid residues. It was tested in 
the CEM-TART (T-cells that express both HIV-1 tat and rev) and HCT-116 colorectal carcinoma cell 
lines with IC50 values of 0.5 and 0.9 µM, respectively. In 2009, theopapuamide A (1) was reported 
along with six new cyclic peptides, theopapuamides B–D (2–4) and celebesides A–C (5–7), from an 
extract of Siliquariaspongia mirabilis collected off Sulawesi Island, Indonesia (Figure 2) [13]. 
Compounds 2, 3, 5, and 7 were tested against HCT-116 cells giving IC50 values of 2.5, 1.3, 9.9, and 
>31 µM, respectively. The ability to inhibit HIV-1 entry was also evaluated for 2, 5 and 7 with IC50 
values of 0.5, 2.1, and >62 µM. Interestingly for celebesides A and C (5,7), in both biological assays, 
loss of activity correlated with the loss of the phosphate group. 1–3 were evaluated for their ability to 
inhibit the growth of both wild type and amphotericin B-resistant strains of Candida albicans.  1 
inhibited the growth of both strains with zones of inhibition of 8 mm at 1 µg/disk while 2 and 3 
displayed zones of 10 mm against both strains at 5 µg/disk. 
Figure 2. Theopapuamide A (1) was isolated from Theonella swinhoei  and 
theopapuamides B–D (2–4) and celebesides A–C (5–7) were isolated from 
Siliquariaspongia mirabilis. 
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A specimen of Siliquariaspongia mirabilis collected off Nama Island, southeast of Chuuk Lagoon, 
in the Federated States of Micronesia yielded the mirabamides A–D (8–11), which are potent 
inhibitors of HIV-1 entry (Figure 3) [14]. 8–11 were tested in an HIV-1 neutralization assay which 
tests a compound’s ability to neutralize the biological effects of the HIV-1 virus on the TZM-bl cell 
line and used two different viral strains: HXB2 (T-cell tropic) and SF162 (macrophage-tropic). Against 
the HXB2 virus, IC50 values for 8, 10, and 11 were 140, 140, and 189 nM and against the SF162 virus, 
8, 10, and 11 were slightly less active with IC50 values of 0.40, 1.01, and 1.31 µM. 8–11 were also 
tested in an HIV-1 fusion assay that tests the ability of a compound to inhibit envelope-mediated cell 
fusion against the LAV (T-cell tropic) viral strain. In the fusion assay, IC50 values for 8, 10, and 11 
were 0.041, 1.3, and 3.9 µM. 9 did not show inhibition in any of the antiviral assays under the 
conditions tested. 8, 10, and 11 were tested against the neutralization assay host cell line, TZM-bl 
showing IC50 values of 1.8, 2.2, and 3.9 µM, respectively. 9 was tested against the HCT-116 cell line 
with an IC50 value of 2.22 µM. Mirabamides E–H (12–15) along with 10 were recently isolated from a 
sponge,  Stelleta clavosa, from the Order Astrophorida collected in the Torres Strait, Queensland, 
Australia (Figure 3) [15]. 10 and 12–15 were tested in the HIV-1 neutralization assay using the viral 
strain YU2-V3 with IC50 values of 123, 121, 62, 68, and 42 nM, respectively. Mirabamides A–D  
(8–11) are very similar in structure to papuamide A (16) but differ by the presence of the novel   
4-chlorohomoproline and β-methoxytyrosine 4′-Ο-α-L-rhamnopyranoside residues (Figure 3) [16]. 9, 
which had no biological activity, contains one additional alteration in which the 2,3-diaminobutanoic 
acid residue is replaced  with 2-amino-2-butenoic acid. Mirabamides E–H (12–15) differ from 8–11 by 
the replacement of the threonine residue with 2-amino-2-butenoic acid. Papuamide A (16) was also 
tested in the fusion assay and against the HCT-116 cell line with IC50 values of 73 nM and 3.5 µM. 
The anti-HIV activity of 16 has recently been determined to be through a membrane targeting 
mechanism in which the hydrophobic tail of the molecule inserts into the viral membrane and the 
tyrosine residue interacts with cholesterol [17]. 
Figure 3. Mirabamides A–D (8–11) were isolated from Siliquariaspongia mirabilis while 
mirabamides E–H (12–15) were isolated from the Astrophorid sponge Stelleta calvosa.  
Papuamide A (16) is a related compound. 
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Figure 3. Cont. 
 
Barangamides A–D (17–20) were isolated from a specimen of Theonella swinhoei collected at 
Baranglompo Island, Indonesia along with theonellapeptolide IIe (21) and a series of previously 
reported theonellapeptolides from the I and II series (Figure 4) [18,19]. The amino acid sequence of 17 
is the same as the cyclic portion of the theonellapeptolide II series but 17 lacks the amino acid side 
chain. In the barangamide series, macrocyclization occurs through peptide bond formation of the 
amine of the threonine rather than through lactonization of the hydroxyl group of threonine as found in 
the theonellapeptolide series. Because theonellapeptolides Ia-Ie were previously known to be 
moderately cytotoxic against the L1210 mouse lymphocytic leukemia cell line, 17 was tested but no 
cytotoxicity was observed at concentrations up to 9.4 μM [18–20]. Cyclic undecapeptides share 
structural similarities with the cyclosporins which are used as immunosuppresants after organ 
transplants [21]. The immunomodulatory activity of the known theonellapeptolides Ia, Id, and IId as 
well as 17 were analyzed in the mixed lymphocyte reaction (MLR) assay [20]. Barangamide A (17) 
showed no activity even at the highest concentration of 94 μM while theonellapeptolide IId showed the 
strongest immunosuppressive activity.  
Nagahamide A (22) was isolated from Theonella swinhoei collected near Nagahama,   
Kamikoshiki-jima Island, Japan (Figure 5) [22]. It was purified using bioassay-guided fractionation 
following anti-fungal activity. Once purified, 22 showed weak antibacterial activity against 
Escherichia coli and Staphylococcus aureus with 7 mm zones of inhibition when tested at 50 μg/disk 
but no antifungal activity was observed against Saccharomyces cerevisiae or Mortierella ramanniana 
at the same dose. Of the seven residues in 22, two were unusual: 8,10-dimethyl-9-hydroxy-7-
methoxytrideca-2,4-dienoic acid (DHMDA) and 4-amino-3-hydroxybutanoic acid (or gamma-amino-
beta-hydroxybutyric acid, GABOB), which is also found in the cytotoxic, anti-fungal 
microsclerodermins [23,24].  Mar. Drugs 2011, 9 
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Figure 4. Barangamides A–D (17–20) and theonellapeptolide IIe (21) were isolated from 
an Indonesian collection of Theonella swinhoei. 
 
Figure 5. Nagahamide A (22) was isolated from a Japanese collection of Theonella 
swinhoei and microsclerodermins F (23) and H (25) were isolated from Microscleroderma sp.  
 
Microsclerodermins A–E were discussed in earlier reviews yet further studies on Microscleroderma sp. 
from a deep-water specimen collected off Short Dropoff, Koror, Palau afforded microsclerodermins F–I 
(23–26) (Figures 5 and 6) [25]. 23–26 showed very similar cytotoxicity against the HCT-116 cell line 
with IC50 values of 1.1, 1.2, 2.0, and 2.6 µM, respectively. They were also tested for the ability to 
inhibit the growth of C. albicans using a paper disk diffusion assay with a minimum concentration in 
which inhibition was observed of 1.5, 3, 12, and 25 mg/disk, respectively. 23–26 differ from 
previously published microsclerodermins by alterations in the ω-aromatic 3-amino-2,4,5-
trihydroxyacid residue and 24 and 26 also have a modification in the tryptophan moiety. The 
dehydromicrosclerodermins C–D (27–28) were isolated as the major constituents from an Okinawan 
collection of Theonella cupola (Figure 6) [26].  
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Figure 6. Microsclerodermin G (24) and I (26) were isolated from a deep-water collection 
of Microscleroderma sp. Dehydromicrosclerodermins C–D (27–28) were isolated from an 
Okinawan collection of Theonella cupola. 
 
From the same family as Microscleroderma, specimens of Scleritoderma nodosum were collected 
from the northwest side of Olango Island, Cebu, Philippines and from Milne Bay, Papua New Guinea. 
These specimens yielded the cytotoxic cyclic peptide, scleritodermin A (29) (Figure 7) [27]. 29 was 
tested against the HCT-116, the HCT-116/VM46 multidrug-resistant colon cancer, the A2780 human 
ovarian carcinoma, and the SKBR3 breast carcinoma cell lines with IC50 values of 1.9, 5.6, 0.940, and  
0.670 µM, respectively. Cell cycle analysis in A2780 cells treated with scleritodermin A (29) for 24 h 
at a concentration of 1.3 µM yielded a G2/M block. As a G2/M block is characteristic of compounds 
that target tubulin, 29 was studied further and found to inhibit GTP-induced tubulin polymerization  
by 50% at a concentration of 10 µM. 29 caused a 5.5-fold increase in the induction of apoptosis  
over the control after a 24 h drug exposure at a concentration close to its cytotoxic IC50. Since   
scleritodermin A (29) had significant in vitro cytotoxicity in human tumor cell lines as well as an  
O-methyl-N-sulfoserine, a novel conjugated thiazole moiety, and an R-ketoamide group, its total 
synthesis was undertaken [28,29]. The initial structure was assigned based upon NOESY data as the 
2Z, 4E configuration for the conjugated thiazole moiety. The structure was revised to the 2E, 4E 
configuration following synthesis based upon the observation of the methine protons, CH-3 and CH-5, 
1.0 ppm further upfield than in the natural product [28,29]. In addition, a difference was observed for 
the chemical shifts of the two methyl groups in the keto-Ile moiety revising the 14R assignment to a 
14S-configuration.  
During an LC-MS screening study by the Crews group to predict which phenotypes of   
Theonella swinhoei contain swinholide A or motuporin, they isolated another series of compounds 
called the isomotuporins A–D (30–33) (Figure 7) [30–35]. The loss of the methoxy group in the  
3-amino-9-methoxy-10-phenyl-2,6,8-trimethyldeca-4,6-dienoic acid (ADDA) residue in isomotuporin 
D (33) is the first report of that variation from a natural source. Most importantly, this study provides 
further assistance for researchers probing for the swinholide or motuporin biosynthetic pathways and 
also demonstrates that some populations produce either 2S-motuporin A or 2R-motuporin A (30).  
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Figure 7. Scleritodermin A (29) was isolated from Scleritoderma nodosum and 
isomotuporins A–D (30–33) were isolated from Theonella swinhoei.  
 
Homophymines A–E (34–38) and A1–E1 (39–43) are a series of cyclodepsipeptides isolated from 
Homophymia sp. collected from shallow waters off the east coast of New Caledonia (Figure 8) [36,37]. 
They are similar in structure to the previously published antiviral marine cyclodepsipeptides, callipeltin 
A, neamphamide A, papuamides, theopapuamides (1–4), and mirabamides (8–15) [12–16,38,39]. 39–43 
differ from 34–38 due to an amide moiety in place of the carboxylic acid on the   
4-amino-2,3-dihydroxy-1,7-heptandioic acid residue. The anti-viral properties of 34 were tested in an 
assay with peripheral blood mononuclear cells (PBMC) infected with the III B strain of HIV-1. 34 had 
cytoprotective properties by inhibiting the production of an infection with an IC50 value of 75 nM. 
Homophymine A (34) was cytotoxic against uninfected PBMC cells with an IC50 of 1.19 µM but it 
was almost sixteen times more effective against infected cells. 34–43 were evaluated against a panel of 
cell lines including human cancer and the Vero green monkey kidney cell lines. 34–43 exhibited potent 
cytotoxicity with IC50 values ranging from 2 to 100 nM. They were the most potent in the PC3 human 
prostate adenocarcinoma and the SK-OV3 human ovarian adenocarcinoma cell lines. Further studies 
were performed on 34–43 to determine if they were toxic or antiproliferative. They were found to 
undergo apoptosis through a caspase independent pathway but were ultimately determined to exert 
their toxicity through an acute direct and non specific mechanism.  
Paltolides A–C (44–46) were isolated from a deep-water specimen of Theonella swinhoei collected 
off Uchelbeluu Reef in Palau (Figure 9) [40]. These are anabaenopeptin-type compounds structurally 
similar to patented compounds isolated from an Australian sponge Melophlus sp. [41]. Compounds 
within the anabaenopeptin class contain an N-methylated amino acid adjacent to and before the   
C-terminal residue which is cyclized to the ε-amine of the lysine residue. 44 contains a standard 
leucine residue at this site and is the first report of an anabaenopeptin-type peptide lacking an   
N-methyl group at this site. These compounds are part of a rare subgroup of the anabaenopeptins since 
they contain a C-terminal tryptophan residue linked to the ε-amine of the N-terminal lysine residue. 
The other compounds within this subgroup are known to inhibit carboxypeptidase U. 44 and 45 did not 
have biological activity in the HIV-1 entry assay or against HCT-116 but their ability to inhibit 
carboxypeptidase U has not been evaluated.  Mar. Drugs 2011, 9 
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Figure 8. Homophymines A–E (34–38) and A1–E1 (39–43) were isolated from a New 
Caledonian collection of Homophymia sp. 
 
Figure 9. Paltolides A–C (44–46) were isolated from a specimen of Theonella swinhoei 
collected in deep-water off Palau. 
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Mutremdamide A (47) was isolated from a few deep-water specimens of Theonella swinhoei 
subspecies swinhoei, Theonella swinhoei subspecies verrucosa, and Theonella cupola collected from 
Mutremdiu Reef, Palau, at depths of 90–120 m using SCUBA (Figure 10) [42]. Mutremdamide A (47) 
is a sulfated cyclic depsipeptide related to perthamide B isolated previously from an Australian 
specimen of Theonella  sp. [43]. 47 differs in three of the eight residues and contains a new   
N
δ-carbamoyl-β-sulfated asparagine residue as well as the rare o-tyrosine residue. Initially, 47 was 
reported as perthamide C isolated alongside perthamide D (48) from Theonella swinhoei collected 
from the barrier reef of Vangunu Island, Solomon Islands (Figure 10) [44]. In the original assignment 
for perthamide C, a β-hydroxyasparagine rather than the N
δ-carbamoyl-β-sulfated asparagine residue 
was proposed but its structure has since been revised to that of 47 [45]. Perthamide D (48) contains a 
phenylalanine in place of the o-tyrosine residue in 47. The anti-inflammatory activity of 47 and 48 was 
evaluated in vivo using the mouse paw edema model [44]. 47 reduced carrageenan-induced paw edema Mar. Drugs 2011, 9 
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in a dose-dependent manner in both early (0–6 h) and late (24–96 h) phases. 47 and 48 displayed a 
60% and 46% reduction of edema at 0.3 mg/kg. Based on current NSAIDs on the market such as 
naproxen (ED50 40 mg/kg), 47 is nearly 100 times more potent. Perthamides E (49) and F (50) were 
isolated from a Theonella swinhoei collected on a reef at a depth of 22 m from the western coast of 
Malaita Island, Solomon Islands (Figure 10) [46]. 47 and 50 have a 3-amino-2-hydroxy-6-
methyloctanoic acid (AHMOA) residue in place of the 3-amino-2-hydroxy-6-methylheptanoic acid 
(AHMHA) residue. Based on the anti-inflammatory activity in the mouse models, 47–50 were 
evaluated for their antipsoriatic effects on TNF-α and IL-8 release using primary human keratinocytes 
(PHK) cells. Although 48 and 50 were too cytotoxic at concentrations up to 10 µM, 47 showed a  
dose-dependent response to inhibit the release of both TNFa and IL-8 and 49 significantly inhibited the 
release of IL-8 [46].  
Figure 10. Mutremdamide A (perthamide C, 47) and perthamides D–F (48–50) were 
isolated from various specimens of Theonella swinhoei. 
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The cytotoxic cyclic peptide lactone, koshikamide B (51), is the first account of a peptide possessing a 
carbamoylated asparagine and the new amino acid residue 2-(3-amino-2-hydroxy-5-oxopyrrolidin-2-yl) 
propionic acid (AHPP) (Figure 11) [47]. It was initially isolated from a Theonella sp. collected off 
Shimokoshiki Island, Kagoshima Prefecture, Japan but was later found in a Theonella sp. collected 
from Palau. It exhibited cytotoxicity against P388 murine leukemia and HCT-116 human colon tumor 
cell lines with IC50 values of 0.22 and 3.7 µM, respectively. Koshikamides F–H (52–54) are 17-residue 
depsipeptides containing a 10-residue macrolactone isolated alongside mutremdamide A (47) (Figures 10 
and 11) [42]. 54 differs from 51 by the substitution of NMeIle with NMeVal. 52 is structurally similar 
to 54 and contains a (Z)-2-(3-amino-5-oxopyrrolidin-2-ylidene) propanoic acid in place of the AHPP 
residue. 53 was determined by MS and NMR to be the descarbamoyl derivative of 52. Compounds 52 
and 54 were tested in a single round HIV-1 neutralization assay against the SF162 strain. In the assay, 
52 and 54 inhibited entry with IC50 values of 2.3 and 5.5 µM, respectively. 54 also had moderate 
cytotoxicity in the HCT-116 colon cancer cell line with an IC50 of 10 µM. 52–54 did not inhibit the 
growth of Candida albicans.  
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Figure 11. Koshikamide B (51) was isolated from Theonella sp. and koshikamides F–H 
(52–54) were isolated from Theonella swinhoei. 
 
 
Solomonamides A and B (55–56) are 4-residue cyclic peptides with a unique   
4-amino-6-(2’-amino-4’-hydroxyphenyl)-3,5-dihydroxy-2-methyl-6-oxohexanoic acid residue isolated 
from the same specimen of Theonella swinhoei that contained perthamides C and D (47–48) (Figures 10 
and 12) [48]. 55 displayed a dose-dependent anti-inflammatory response causing nearly a 60% 
reduction of edema in mice at a dose of 100 μg/kg (ip.). The absolute configuration of 55 was 
established through extensive work including Marfey’s method, Quantum Mechanical J  based 
analysis, and Density Functional Theory (DFT) J/
13C calculations.  
Figure 12. A collection of Theonella swinhoei from the Solomon Islands yielded 
solomonamides A and B (55,56). 
 Mar. Drugs 2011, 9 
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3. Linear Peptides  
Miraziridine A (57) is a linear five amino acid peptide isolated from a specimen of Theonella aff. 
mirabilis collected off the Amami and Tokara Islands, Japan (Figure 13) [49]. It contains the rare  
aziridine-2,3-dicarboxylic acid residue that has only been reported one other time from a Streptomyces sp. 
and also a vinylogous arginine residue that has never before been reported from a natural source. 57 
inhibited the enzymatic activity of cathepsin B with an IC50 value of 2.1 µM. The total synthesis of 57 
has been completed (discussed later in this review [50,51]). 
Figure 13. Miraziridine A (57) was isolated from a Japanese collection of Theonella  
aff. mirabilis. 
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Koshikamide A2 (58) was isolated from a Theonella sp. collected off Shimo-koshiki-jima Island, 
Kagoshima, Japan (Figure 14) [52]. The structure of 58 was determined to be a close structural 
homolog of the previously described Koshikamide A1 with an additional arginine residue added to the 
C-terminus. 58 was cytotoxic to P388 murine leukemia cell line with an IC50 value of 4.6 µM whereas 
Koshikamide A1 was more cytotoxic with an IC50 value of 1.7 µM.  
Figure 14. Koshikamide A2 (58) was isolated from a Japanese collection of Theonella sp. 
 
Koshikamides C–E (59–61) are linear undecapeptides isolated alongside 47, and 52–54 (Figures 10, 
11, and 15) [42]. Their structures were determined by extensive NMR and mass spectrometry. 59 was 
observed to exist as two stable conformers due to cis/trans isomerization. They were tested in a single 
round HIV-1 infectivity assay against a CCR5-using viral envelope but no biological activity   
was observed.  
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Figure 15. Koshikamides C–E (59–61) were isolated from various specimens of Theonella 
swinhoei and T. cupola from the reefs of Palau. 
 
Polytheonamides A (62) and B (63) were isolated from a specimen of Theonella swinhoei   
collected off Hachijo-jima Island, Japan and initially reported in 1994 by the Fusetani group at Tokyo 
University (Figure 16) [53,54]. During their studies to determine the configuration of 62 and 63, they 
realized the initially proposed structure was incorrect and determined the new structure by spectral and 
chemical methods, relying heavily on 2D NMR experiments [53]. 62 and 63 are 48 amino acid residue 
polypeptides with numerous unprecedented structural features such as the unusual N-terminal blocking 
group, the first report from a natural source of the 5,5-dimethyl-2-oxoheptanoyl group, the presence of 
eight rare t-Leu residues from a marine source, and the first report of the residue   
β,β-dimethylmethionine sulfoxide. 62 and 63 are isomeric at the sulfoxide moiety on the 44th residue. 
62 and 63 are the largest non-ribosomal peptides with an alternating D/L stereochemistry throughout 
the chain seen only once before in gramicidin A, which is a linear 15-residue peptide produced by 
Bacillus brevis [55].  
4. Polyketides and Macrolides 
Hurghadolide A (64) and Swinholide I (65) were isolated from a specimen of Theonella swinhoei 
collected in Hurghada at the Egyptian Red Sea coast (Figure 17) [56]. Hurghadolide A (64) is one 
acetate unit shorter than 65 and therefore has an unprecedented asymmetric 42-membered dilactone 
moiety which represents a new macrolide carbon skeleton. Swinholide I (65) is similar in structure to 
swinholide A and is the first swinholide derivative with hydroxylation on the side chain [57]. 64 and 
65 showed very potent in vitro cytotoxicity against HCT-116 with IC50 values of 5.6 and 365 nM, 
respectively, as well as disruption of the actin cytoskeleton at concentrations of 70 and 7.3 nM, 
respectively. Also, both compounds were tested for their ability to inhibit the growth of C. albicans 
with MIC values of 31.3 and 62.2 µg/mL, respectively. Swinholide J (66) was isolated from a 
specimen of Theonella swinhoei collected on the reef off Vangunu Island, Solomon Islands (Figure 18) 
[58]. 66 has an unprecedented asymmetric 44-membered dilactone moiety and contains an epoxide 
functionality in one half of the molecule. 66 and swinholide A showed very potent in vitro cytotoxicity Mar. Drugs 2011, 9 
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against the KB nasopharyngeal epidermoid carcinoma cell line with IC50 values of 6.7 and 1.2 nM, 
respectively.  
Figure 16. The 48-residue linear peptides, polytheonamides A and B (62,63), were isolated 
from a Japanese collection of Theonella swinhoei. 
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Figure 17. Hurghadolide A (64) and swinholide I (65) were isolated from an Egyptian 
collection of Theonella swinhoei.  
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In 2005, the Gerwick group reported the isolation of swinholide A (initially isolated in 1985 from 
the sponge Theonella swinhoei) and two glycosylated derivatives, ankaraholide A (67) and B (68), for 
the first time from field collections of two species of cyanobacteria (Figure 18) [7]. Specimens of 
Symploca cf. sp. that produced swinholide A were collected from the Fiji Islands while specimens of 
Geitlerinema sp. collected from Nosy Mitso-ankaraha Island, Madagascar produced 67 and 68. This 
discovery as well as the fact that the swinholides are produced by three taxonomically unrelated 
sponges suggests that symbiotic microorganisms may be the true producers of these metabolites. Since 
the swinholides cause cytotoxicity by disrupting the actin cytoskeleton, the effects of the added sugar 
moiety were evaluated. 67 caused cytotoxicity in NCI-H460 human large cell lung cancer, Neuro-2a 
mouse brain neuroblast, and MDA-MB-435 human melanoma cell lines with IC50 values of 119, 262, 
and 8.9 nM, respectively. In A-10 aortic smooth muscle cells, 68  caused the complete loss of 
filamentous actin at 30 and 60 nM which is consistent with the disruption of the actin cytoskeleton.  
Figure 18. Swinholide J (66) was isolated from Theonella swinhoei and ankaraholides A 
and B (67,68) were isolated from the cyanobacteria, Geitlerinema sp. 
 
A new calyculinamide-related congener called swinhoeiamide A (69) was isolated from Theonella 
swinhoei  collected off the coast of the Karkar Island, Papua New Guinea (Figure 19) [59]. The 
structure of the new compound was assigned on the basis of 1D and 2D NMR spectroscopy and 
HRMS data. 69 differs from calyculinamide A by replacement of the complex side chain attached to 
C-29 in the oxazole ring system with a methyl substituent and 69 is also the first calyculin congener in 
which the double bond at C-4 and C-5 is hydrogenated [60]. 69 exhibited insecticidal activity toward 
the neonate larvae of the insect Spodoptera littoralis in a chronic feeding bioassay with an effective 
dose, 50% (ED50) value of 2.11 ppm and a median lethal dose (LD50) value of 2.98 ppm. 69 was found 
to inhibit the growth of C. albicans and Aspergillus fumigatus with MIC values of 1.2 and 1.0 µg/mL, 
respectively. 69 also exhibited dose-dependent cytotoxicity against various undisclosed cell lines and 
tissues with IC50 values ranging between 20 and 90 ng/mL. Another calyculin A derivative, 
hemicalyculin A (70), was isolated from Discodermia calyx collected off Sikine-jima Island, Japan 
(Figure 19) [61]. The structure of 70 is comprised of just the southern hemisphere of calyculin A and 
allowed the Fusetani group to pursue structure-activity relationships providing further insight into the Mar. Drugs 2011, 9 
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binding of calyculin A with protein phosphatases 1 and 2A (PP1 and PP2A) [61–64]. 70 was tested 
alongside calyculin A to determine its ability to inhibit PP1 and PP2A with IC50 values of 14.2 nM and 
1.0 nM versus 8.2 nM and 1.0 nM of calyculin A.  
Figure 19. Swinhoeiamide A (69) was isolated from a Papua New Guinea collection of 
Theonella swinhoei. Hemicalyculin (70) was isolated from a Japanese collection of 
Discodermia calyx. 
 
Bitungolides A–F (71–76) were isolated from a specimen of Theonella cf. swinhoei collected along 
the Lembeh Strait off Bitung, Sulawesi Island, Indonesia (Figure 20) [65]. The structure of 71 was 
confirmed by a single-crystal X-ray diffraction study. Bitungolides are structurally similar to pironetin 
reported previously from a Streptomyces sp. [66]. Pironetin shows moderate in vivo anti-tumor activity 
and arrests cells at the M-phase of the cell cycle [67]. 71–76 were tested against a number of 
phosphatases and showed no activity against protein tyrosine phosphatase-S2 (PTP-S2), PP1, or PP2A. 
71–76 showed weak activity against dual-specificity protein phosphatase vaccinia H1-related (VHR). 
The total synthesis of bitungolide F has been completed and will be discussed in a later section [68].  
Figure 20. Bitungolides A–F (71–76) were isolated from an Indonesian collection of 
Theonella cf. swinhoei. 
 
Leiodolides A (77) and B (78) were isolated from a new species of the deep-water sponge 
Leiodermatium sp. collected at 240 m near Uchelbeluu Reef in Palau using the manned submersible 
Deep Worker (Figure 21) [69]. 77 and 78 are the first published compounds from this genus of sponge. 
The leiodolides represent the first members of a new class of 19-membered ring macrolides and they 
incorporate several unique functional groups such as a conjugated oxazole ring, a bromine substituent, 
and an α-hydroxy-α-methyl carboxylic acid side-chain terminus. 77 and 78 were cytotoxic against the 
HCT-116 cell line with IC50 values of 2.5 and 5.6 µM, respectively. In the NCI 60 cell line panel, 
leiodolide A (77) was cytotoxic to the HL-60 leukemia, the NCI-H522 non-small cell lung cancer, and 
the OVCAR-3 ovarian cancer cell lines with growth inhibition, 50% (GI50) values of 0.26, 0.26, and Mar. Drugs 2011, 9 
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0.25 µM, respectively. Recently, a total synthesis of the proposed structure for leiodolide B (78) was 
published, but its spectroscopic data did not match those of the authentic sample [70]. This will be 
discussed in a later section. 
Figure 21. Leiodolides A and B (77,78) were isolated from a deep-water sponge, 
Leiodermatium sp. collected in Palau. 
 
Leiodermatolide (79) was isolated from Leiodermatium sp. collected on the Miami Terrace in the 
Straits of Florida at 401 m using the Johnson-Sea-Link submersible (Figure 22) [71]. It has a   
16-membered macrolide ring with a carbamate and a substituted lactone in the side chain. 79 was 
isolated by bioassay guided fractionation following a Phospho-nucleolin Cytoblot Assay where 79 
showed potent inhibition of mitosis. Further studies found that 79 induced a G2/M block in the cell 
cycle. 79 was tested against the A549 human lung adenocarcinoma, the NCI-ADR-RES human ovarian 
sarcoma, the P388 murine leukemia, the PANC-1 human pancreatic carcinoma, and the DLD-1 
colorectal adenocarcinoma cell lines with very potent IC50 values of 3.3, 233, 3.3, 5.0, and 8.3 nM.  
Figure 22. Leiodermatolide (79) was isolated from a Floridian collection of the deep-water 
lithistid, Leiodermatium sp. 
 
Collections of Discodermia  sp. obtained using the Johnson-Sea-Link submersible in   
numerous places throughout the Bahamas yielded five new discodermolide analogues:   
2-epidiscodermolide (80), 2-desmethyldiscodermolide (81), 5-hydroxymethyl- discodermolide (82), 
19-des-aminocarbonyldiscodermolide (83), and 9(13)-cyclodiscodermolide (84) (Figure 23) [72]. 
Based on these five natural analogs as well as numerous synthetic derivatives, information about the 
structure-activity relationship of discodermolide was obtained. Discodermolide and its naturally 
occurring analogues 80–84 were tested against the P-388 cell line with IC50 values of 35, 134, 172, 
65.8, 128 and 5043 nM as well as the A-549 cell line with IC50 values of 13.5, 67, 120, 74, 74 and 
4487 nM [72,73]. This data indicated that alterations in the δ-lactone ring have a minor contribution 
toward the activity but changes at the diene end of the molecule had no significant decrease in activity. 
Complete loss of activity was observed when alterations were made in the middle section of the Mar. Drugs 2011, 9 
 
 
2660
molecule. This data was in agreement with earlier findings that the C-7 through C-17 backbone, which 
adopts a hairpin conformation, is essential to the cytotoxicity of discodermolide [74,75].  
Figure 23. Five new discodermolide analogues reported from Discodermia  sp.:  
2-epidiscodermolide (80), 2-desmethyldiscodermolide (81), 5-hydroxymethyl- discodermolide 
(82), 19-des-aminocarbonyldiscodermolide (83), and 9(13)-cyclodiscodermolide (84). 
 
Neopeltolide (85) was isolated from two samples of sponge from the Family Neopeltidae   
collected using the Johnson-Sea-Link submersible at depths of 442 and 433 m off the northwest coast 
of Jamaica (Figure 24) [76]. 85 is a potent inhibitor of the proliferation of the A-549, NCI-ADR-RES, 
and P388 cell lines with IC50 values of 1.2, 5.1, and 0.56 nM, respectively. 85 also inhibits the growth 
of  C. albicans with an MIC of 0.62 µg/mL. 85  is structurally homologous to the potent 
antiproliferative compound leucascandrolide A and the cytochrome bc1 complex was found to be the 
primary cellular target of both compounds [77]. Based on its potent biological activity and similarity to 
leucascandrolide A, 85 was targeted by numerous synthetic groups to complete its total synthesis and 
absolute configuration. The relative configuration of 85 was suggested as 11R, 13R based on coupling 
constant analysis, 2D-NOESY, and a series of double-pulsed field gradient spin echo (DPFGSE) NOE 
experiments but once it was synthesized, its configuration was reassigned to 11S, 13S [78,79]. The 
total synthesis of 85 will be discussed in a later section.  
Mirabalin (86), initially reported as mirabilin, was isolated from Siliquariaspongia mirabilis 
collected southeast of Chuuk lagoon in the Federated States of Micronesia (Figure 24) [80,81]. 86 is 
characterized by the presence of a 35-membered macrolide lactam ring bearing a pentadiene 
conjugated system, a tetra-substituted tetrahydropyran ring, and a linear polyketide moiety attached to 
the macrolide ring via an amide linkage. 86 inhibited the growth of the HCT-116 cell line with an IC50 
value of 0.27 µM and was not cytotoxic to several other cell lines tested. 86 is the first macrolide of 
the chondropsin family with a conjugated pentadiene and a tetrasubstitued tetrahydropyran ring as well 
as being the first such macrolide to be isolated from a member of the Theonellidae family. Mirabalin 
was difficult to work with as it was unstable in ambient light and degraded within 3–4 h. Mar. Drugs 2011, 9 
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Figure 24. Neopeltolide (85) was isolated from a deep-water sponge of the Family 
Neopeltidae.  Mirabalin (86), initially published as mirabilin, was isolated from 
Siliquariaspongia mirabilis. 
 
Dictyostatin-1 (87) was initially isolated in 1994 from a marine sponge in the genus Spongia sp. but 
in 2003, it was isolated from a Corallistidae (now revised to be Neopeltidae) collected using the 
Johnson-Sea-Link submersible at a depth of 442 m off the north coast of Jamaica (Figure 25) [82,83]. 
In initial studies, dictyostatin-1 arrested cells in the G2/M phase of the cell cycle [82]. 87 has been 
shown to be a potent promoter of tubulin assembly similar to paclitaxel and discodermolide (133) [84]. 
It has recently been synthesized and is also being used in work by the Paterson and Curran/Day 
Groups to make discodermolide-dictyostatin analogs [85–91].  
Theopederin F–J (88–92) were isolated from T. swinhoei collected off the Kerama Islands, Ryukyu 
Archipelago, Japan (Figure 25) [92]. 88 inhibited the growth of wild type S. cerevisiae with an 11 mm 
inhibitory zone at 10 pg/disk and against the erg6 mutant with a 12 mm inhibitory zone at 1 µg/disk. 
88 was also found to be cytotoxic to the P388 cell line with an IC50 value of 0.28 nM. 89–92 exhibited 
similar activities but could not be evaluated due to sample constraints. Theopederins K (93) and L (94) 
were isolated from four specimens of Discodermia sp. collected by the Johnson-Sea-Link submersible 
at depths of 121–125 m off the north coast of Honduras (Figure 25) [93]. 93 and 94 exhibited potent 
 in vitro cytotoxicity against the P-388 cell line with IC50 values of 0.1 and 7.3 nM and the A-549 cell 
line with IC50 values of 1.5 and 3.2 nM, respectively. They are all derivatives of theopederin A and B 
and mycalamide A with the major difference being alterations in the side chain [94,95].  
Four new analogs of onnamide A named 21,22-dihydroxyonnamides A1–A4 (95–98) were isolated 
from a polar fraction of Theonella swinhoei collected off Okinawa, Japan (Figure 26) [96]. Due to 
isomerism around the diol, they could only be separated after conversion to isopropylidene derivatives. 
A 2:2:2:1 isomeric mixture inhibited the P388 cell line with an IC50 value of 46 nM, but each one 
alone did not have the same cytotoxicity. Recently, the Piel group at the University of Bonn, Germany 
isolated the biosynthetic gene cluster for onnamide A from the metagenome of Theonella swinhoei [9]. 
Their research showed that onnamide A was clearly produced by a bacterial symbiont and not the host 
sponge [9].  
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Figure 25. Dictyostatin-1 (87) was isolated from a deep-water sponge of the Family 
Neopeltidae.  Theopederin F–J (88–92) were isolated from a Japanese collection of 
Theonella swinhoei. Theopederin K and L (93,94) were isolated from deep-water 
specimens of Discodermia sp. 
 
Figure 26. Four onnamide A analogs, 21,22-dihydroxyonnamides A1–A4 (95–98), were 
isolated from an Okinawan collection of Theonella swinhoei. 
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5. Sterols, Lipids, and Fatty Acids 
Lysoplasmanylinositols 1 (99) and 2 (100) were isolated from a collection of T. swinhoei with a 
white interior off Hachijo-jima Island, Japan (Figure 27) [97]. 100 inhibited the growth of E. coli at  
50 µg/disk with a 12 mm inhibitory zone but activity was only observed for 99 through bioautography. 
Related lysophosphatidylinositols have been previously isolated from the ascidian Halocynthia roretzi as 
antifungal constituents but this is the first report of lysoplasmanylinositols isolated from a marine 
organism [98].  
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Figure 27. Lysoplasmanylinositols 1 and 2 (99,100) were isolated from a Japanese 
collection of Theonella swinhoei. 
 
Calyceramides A–C (101–103) were isolated from Discodermia calyx collected off Sikine-jima 
Island, Japan (Figure 28) [99]. They are sulfated ceramides that inhibit neuraminidase with IC50 values 
of 0.63, 0.32, and 1.3 µM, respectively. They are very closely related to the ceramide 1-sulfates, which 
are inhibitors of DNA topoisomerase I isolated from the bryozoan Watersipora cucullata [100].  
Figure 28. Calyceramides A–C (101–103) were isolated from a Japanese collection of 
Discodermia calyx.  
 
Discoside (104) was isolated from Discodermia dissoluta collected off the coast of Little San 
Salvador, Bahamas (Figure 29) [101]. 104 is the first example of a 4,6-O-diacylated mannose attached 
to the 2-hydroxyl group of a myo-inositol unit. Compounds similar to 104 have not been reported from 
marine sponges and the only analogue of 104 reported previously was isolated from various strains of 
Propionibacterium [102].  
Azoricasterol (105) is the first metabolite isolated from Macandrewia azorica (Figure 29) [103]. 
The specimen was collected from a depth of 600 m off the flanks of the Gettysburg and Ormonde Sea 
Mount in the North Atlantic by benthic dredging. 105 has an unusual side chain that has two additional 
methyl groups and a quaternary center forming a rare elongated side chain for sterols.  
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Figure 29. Discoside (104) was isolated from a Bahamian collection of Discodermia 
dissoluta. Azoricasterol (105) was isolated from a deep-water specimen of   
Macandrewia azorica. 
 
Motualevic acids A–F (106–111) were isolated along with a new enantiomer of antazirine,   
(4E)-R-antazirine (112), from the marine sponge Siliquariaspongia sp. collected on the Motualevu  
reef in Fiji (Figure 30) [104]. 106–109 are the first glycyl conjugates of the ω-brominated lipid   
(E)-14,14-dibromotetradeca-2,13-dienoic acid and 111 is the first long-chain 2H-azirine 2-carboxylic 
acid to be found in nature. The carboxylic acid-containing compounds 106 and 111 were found   
to inhibit the growth of S. aureus with MIC50 values of 10.9 and 1.2 µg/mL as well as   
methicillin-resistant S. aureus with MIC50 values of 21 and 9.3 µg/mL, respectively.  
Figure 30. Motualevic acids A–F (106–111) and (4E)-R-antazirine (112) were isolated 
from a Fijian collection of Siliquariaspongia sp. 
 
Aurantosides G–I (113–115) were isolated from T. swinhoei collected in Milne Bay, Papua New 
Guinea (Figure 31) [105]. They are similar to aurantoside A but have one less chlorinated methylene 
unit in the polyene side chain [106]. Also, while aurantoside A is a trisaccharide, 113 is a 
monosaccharide and 114 is a disaccharide. 113–115 did not inhibit the HCT-116 colorectal carcinoma 
cell line when tested at 152, 124, and 103 µM, respectively. They were also inactive in an anti-HIV 
assay when tested at concentrations of 20, 15, and 12.8 µM, respectively. Aurantoic acid (116) is a Mar. Drugs 2011, 9 
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chlorinated polyene moiety that is evident in the structures of the 113–115 (Figure 31) [30]. 116 was 
isolated from T. swinhoei collected at a depth of 20–50 m in Bunaken Marine Park, North Sulawesi, 
Indonesia along with dehydroconicasterol (120, discussed later). 116 showed minimal inhibition when 
tested at a concentration of 70 µM against C6 glioma, HeLa epithelial carcinoma, and H9c2 cardiac 
myoblast cell lines.  
Figure 31. Aurantosides G–I (113–115) and aurantoic acid (116) were isolated from 
Theonella swinhoei. 
 
Sponges of the genus Theonella are known to produce biosynthetically unique 4-methylene sterols 
and these may be ideal taxonomic markers [107]. Recently, a series of conicasterol and theonellasterol 
derivatives (117–130) were isolated from Theonella swinhoei collected from Yongxing Island in the 
South China Sea, at Panglao Island, Bohol, Philippines, on the barrier reef of Vangunu and Malaita Island, 
Solomon Islands, and at Bunaken Marine Park, North Sulawesi, Indonesia (Figure 32) [30,107–109].   
9α-hydroxy-15-oxoconicasterol (117) and 8β-hydroxy-B-norconicasta-6α-aldehyde (118) have novel 
hydroxyl substitution at either the C-9 or C-8 position and 118  has a B-nor-framework [107].   
7α-hydroxytheonellasterol (119) has an additional hydroxyl group at C-7 and an ethyl group   
at C-24 when compared to the known compounds theonellasterol and swinhosterol C [110,111]. 
Dehydroconicasterol (120) was isolated alongside aurantoic acid (116) and showed minimal inhibition 
when tested at a concentration of 70 µM in C6, HeLa, and H9c2 cell lines [30]. The biological activity 
of 117 and 118 has not evaluated but 119 showed cytotoxicity against an undisclosed panel of eight 
cell lines with a mean IC50 value of 29.5 µM [109]. Theonellasterols B–H (121–127) and conicasterols 
B–D (128–130) were evaluated for their ability to affect the nuclear receptors, pregnane-X-receptor 
(PXR) and farnesoid-X-receptor (FXR) [108]. Using a HepG2 human hepatoma reporter cell line 
transfected with FXR or PXR, 126 partially activated FXR at 10 µM and 121, 122, 124, and 126–130 
were effective antagonists of FXR transactivation by chenodeoxycholic acid. All of the compounds 
(121–130) were agonists of PXR at 10 µM. 126 is one of the first natural products that modulates FXR 
and is also a ligand for PXR. A molecular docking study was conducted for 121–128 and 130 to 
determine structure-activity relationships [108].  
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Figure 32. New conicasterol and theonellasterol derivatives (117–130) isolated from 
numerous collections of Theonella swinhoei. 
 
Malaitasterol A (131) is an unprecedented secosterol isolated from Theonella swinhoei collected at 
a depth of 22 m off the western coast of Malaita Island, Solomon Islands (Figure 33) [112]. Its unique 
11, 12, 13, 14-bis-secosteroid structure was determined by extensive spectroscopic analysis and DFT 
13C calculations. It is structurally similar to the other known 4-methylene sterols 117–130  but its   
bis-secosteroid structure has not been observed from natural sources. It was found to be a potent 
inducer of PXR transactivation at a concentration of 10 µM with no effect on FXR. Its PXR activity 
was confirmed by an increase in the gene expression of downstream PXR targets as well as in 
molecular docking studies.  
Figure 33. Malaitasterol A (131) was isolated from Theonella swinhoei collected in the 
Solomon Islands. 
 
6. Alkaloids 
Collections of Discodermia polydiscus from the north point of the Acklins Island, Bahamas and off 
Grand Bahama Island yielded the discodermindole analog; 6-hydroxydiscodermindole (132) in trace Mar. Drugs 2011, 9 
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amounts (Figure 34) [113]. 132 inhibited the proliferation of the P388 cell line with an IC50 value of 
12.4 µM.  
Figure 34. The discodermindole analog, 6-hydroxydiscodermindole (132), was isolated 
from Bahamian collections of Discodermia polydiscus.  
 
7. Recent Total Synthesis of Lithistid Natural Products 
The total synthesis of a number of lithistid derived compounds has been achieved over the past 
decade. Some of these syntheses resulted in the reassignment of the initially proposed relative 
configurations while some allowed for the assignment of absolute configurations.  
Discodermolide  (133) inhibits cell proliferation by polymerizing and hyperstabilizing tubulin 
similar to paclitaxel but shows activity against paclitaxel resistant tumors (Figure 35). A number of 
syntheses have been previously reviewed for 133 but the large-scale synthesis accomplished during 
this decade was very important to provide enough of the compound for clinical trials [5,73,114–116]. 
Despite the other microtubule-stabilizing agents discovered, 133 is the most potent natural promoter of 
tubulin assembly discovered to date [116,117]. Though clinical trials have been halted, more recent 
research has shown that discodermolide and paclitaxel have a synergistic effect when used in 
combination [118]. Some excellent reviews have been published that discuss the different approaches 
used in the synthesis of discodermolide [85,116,119].  
Figure 35. A multi-gram total synthesis of discodermolide (133) was completed in order 
for Novartis to begin Phase I clinical trials. 
 
There have been a number of total syntheses published on dictyostatin-1 (87) [86,91,120,121].  
An excellent review was recently published that discusses the different synthetic approaches used in 
the total synthesis of dictyostatin-1 (87) (Figure 25) [85]. In the review, some of the exciting work on 
the synthesis of discodermolide analogs, dictyostatin-1 analogs, and discodermolide-dictyostatin-1 
hybrids is also discussed [84–91,120,122–127].  Mar. Drugs 2011, 9 
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Callipeltoside A (134) was isolated from a specimen of Callipelta sp. collected off New Caledonia 
in 1996 (Figure 36) [128]. 134 inhibited the proliferation of the KB and P388 cell lines and, in the 
NSCLC-N6 non-small-cell bronchopulmonary carcinoma cell line, 134 arrested cells in the G1 phase. 
Based on its stereochemical and structural complexity coupled with its unique biological activity, 
members of the callipeltoside family became attractive targets for total synthesis. The first total 
synthesis of 134 was a convergent synthesis that focused on making three main pieces: the macrolide, 
the side chain, and the sugar with an overall yield of 0.47% in 50 steps [129]. Other syntheses have 
been published by the Evans group at Harvard University, the Panek group at Boston University, and 
the Paterson group [130–132]. Their different synthetic approaches increased the overall yield to a 
maximum of 4.8% with a longest linear sequence of 23 steps [132]. Callipeltoside C (135) was 
recently synthesized resulting in the revision of the absolute configuration around its sugar moiety 
(Figure 36) [133,134]. It was completed with a longest linear sequence of 20 steps in 11% overall yield.  
Figure 36. The total syntheses of callipeltoside A (134) and C (135) were completed with 
the longest linear sequences of 23 and 20 steps, respectively.   
 
Callipeltin B (136) is an eight-residue cyclic depsipeptide isolated from Callipelta sp. collected off 
New Caledonia (Figure 37) [135]. 136 was found to inhibit the proliferation of the KB, P388, and 
NSCLC-N6 cell lines. It is structurally similar to callipeltin A whose structure was revised after its 
original publication although its total synthesis has not been completed [39,136,137]. The total 
synthesis of 136 was completed using a solid-phase support with a 15% overall yield. By comparing 
data with the original proposed structure, the configuration of 136 was reassigned from 18S, 21S to 
18R, 21R. A series of callipeltin analogs have since been synthesized and analyzed for their ability to 
inhibit the HeLa cervical adenocarcinoma cell line [138].  
Reidispongiolide A (137)  is a polyketide containing a 26-member macrolide ring which was 
isolated from a specimen of Reidispongia coerulea collected off New Caledonia (Figure 38) [139,140]. 
It is a member of the sphinxolide/reidispongiolide class of macrolides which are members of an 
emerging class of actin-binding cytotoxic macrolides [139]. The absolute configuration of 
reidispongiolide A  had not been determined; therefore the Paterson group carried out the total 
synthesis defining it as shown in 137. They completed the total synthesis with a longest linear 
sequence of 25 steps in a 1.1% overall yield [141].  Mar. Drugs 2011, 9 
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Figure 37. The total synthesis of callipeltin B (136) revised its structure from 18S, 21S to 
18R, 21R. 
 
Figure 38. The absolute configuration of reidispongiolide A (137) was determined through 
total synthesis.   
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Neopeltolide (85) has received significant attention from synthetic chemists since its publication in 
2007 due to its interesting structural aspects and potent biological activity (Figure 24) [76]. The first 
total synthesis of 85 was completed by the Panek group and had a longest linear sequence of 19 steps 
with an overall yield of 1.3% [78]. It was determined from this initial synthesis that the 
stereochemistry, which was originally proposed as 11R, 13R, is actually 11S, 13S. A number of 
syntheses followed and all were in agreement with the Panek group’s initial observation [77–79,142–144]. 
The highest yielding synthesis to date was reported by the Fuwa/Sasaki group at Tohuku University 
which prepared 85  with the longest linear sequence of 25 steps and an 8.3% overall yield [142]. 
Synthetic neopeltolide analogs have been tested against a variety of human, murine, and bovine cell 
lines to obtain valuable SAR information [145].  
Papuamide B (138) is a 22-membered cyclic depsipeptide connected to a complex linear tetrapeptide 
via an amide linkage (Figure 39) [16]. Both papuamide A (16) and B (138) exhibit a potent inhibitory 
effect on the infection of human T-lymphoblastoid cells by HIV-1RF with an EC50 value of 4 ng/mL. 
The total synthesis of 138 was completed by the Ma Group at the Chinese Academy of Sciences and 
suggested a revision of the 2,3-diaminobutanoic acid in the side chain from 2S, 3R to 2S, 3S [146]. The 
papuamides are structural analogs of the mirabamides (8–15)  and have very similar biological Mar. Drugs 2011, 9 
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activities. This synthetic scheme is amenable to complete the total synthesis of closely related 
compounds as well as determine SAR information.  
Figure 39. The absolute configuration of papuamide B (138) was revised based on the  
total synthesis.  
 
Superstolide A (139) is a macrolide isolated from Neosiphonia superstes collected off New 
Caledonia (Figure 40) [147]. It is highly cytotoxic against several cancer cell lines including the P388, 
human nasopharyngeal KB, and NSCLC-N6-L16 non-small cell lung carcinoma cell lines with IC50 
values of 5, 8, and 6 nM, respectively [147]. Due to their interesting chemical structures and potent 
biological properties, the superstolides have attracted considerable attention as synthetic targets. The 
Roush group at Scripps Florida reported the total synthesis in 2008 [148]. Their synthetic route was 
likely biomimetic in nature and utilized an intramolecular Suzuki coupling reaction and a highly 
stereoselective transannular Diels-Alder cycloaddition [148].  
Figure 40. The total synthesis of superstolide A (139) and microsclerodermin E (140) have 
recently been achieved.  
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Microsclerodermin E (140) and its series of cyclic peptides were isolated by Faulkner and   
co-workers at Scripps Institute of Oceanography (Figure 40) [24]. Structurally, each of them contains 
several unique features, including a 23-membered cyclic hexapeptide core, featuring a very complex  
β-amino acid and three other unnatural amino acid residues. The Ma group at the Chinese Academy of 
Sciences reported the first total synthesis of a member of the microsclerodermin group with a 1% 
overall yield in 26 linear steps [149]. 
Scleritodermin A (29) was recently isolated from Scleritoderma nodosum (Figure 7) [27]. It has an 
interesting structure and was found to have potent biological activities as well as cause cell cycle arrest 
in the G2/M phase. The total synthesis was undertaken by the Nan group at the Chinese Academy of 
Sciences and the structure was revised from 2Z, 4E and 14R to 2E, 4E and 14S [28].  
Cyclotheonamides E2 (141) and E3 (142) are cyclic pentapeptides found to be potent inhibitors  
of serine proteases (Figure 41) [150]. Because of their biological properties and unusual structural 
features, further research was done on their mode of enzyme inhibition as well as their total synthesis. 
141 and 142 are structurally similar to cyclotheonamides A and B, both of which have been 
synthesized previously [151–153]. The differences are a D-alloisoleucine in place of D-phenylalanine 
as well as the addition of the benzoylalanine and isovalerylalanine side chain [151]. The Wasserman 
group at Yale University synthesized 141 and 142 using a cyano ylide method [154].  
Figure 41. Cyclotheonamides E2 and E3 (141,142) are potent inhibitors of serine proteases 
and their total synthesis has been completed. 
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Miraziridine A (57) is structurally similar to known compounds that are inhibitors of trypsin-like 
serine proteases, papain-like cysteine proteases, and pepsin-like aspartyl proteases (Figure 13) [49]. 
The total synthesis of 57 was completed by Schaschke at the Max-Planck-Institut für Biochemie in 
order to use 57 as a blueprint to efficiently design small molecule protease inhibitors [51]. The Konno 
group at the Kyoto Prefectural University of Medicine produced 57 as well as a number of analogs to 
provide important SAR information [50]. They determined that the N-terminal aziridine is important 
for cathepsin B inhibition. 
Leiodolide B (78) was recently isolated from a deep-water sponge Leiodermatium sp. by the Fenical 
group (Figure 21) [69]. Since only a very small amount (0.8 mg) could be isolated from the natural Mar. Drugs 2011, 9 
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source, its structure was determined based on comparisions with leiodolide A (77) and a proposed 
biosynthetic closure of the brominated tetrahydrofuran ring [69]. The Fürstner group at the Max-
Planck-Institut für Kohlenforschung prepared four isomers of 78 yet none of them matched the NMR 
data of the natural product [70]. Further work is being performed by the Fürstner group to synthesize 
leiodolides A and B.  
Bitungolide F (76) was isolated from an Indonesian collection of Theonella cf. swinhoei (Figure 20) [65]. 
76 is structurally similar to pironetin, a compound isolated from Streptomyces sp. which arrests cell at 
the M-phase of the cell cycle [65]. The structure of bitungolide A (71) had been confirmed by X-ray 
and the structure of 76 was based on comparison with 71. The She group from Lanzhou University, 
China completed the total synthesis of 76 in 17 steps with a yield of 20.1% [68].  
8. Conclusion 
From the unique activities and amazing diversity of the compounds isolated just over the past 
decade, sponges from the Order Lithistida will almost certainly continue to be a significant source of 
interesting biologically active compounds. Recent research has shown that some of the compounds 
isolated from sponges within this order are likely produced by the microorganisms residing within 
them and work is ongoing to culture these microbes [1,7,67]. A future area of research will be to 
understand what unique characteristics of lithistid sponges leads to such a great diversity of microbes 
and ultimately such a diverse array of compounds. 
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